Kestra Medical Projects FY27 Revenue of $137M, Topping Views
KMTS sits 82% above its 52-week low of $13.25.
Summary
Kestra Medical guided for FY27 revenue of $137 million, a figure that likely exceeds consensus expectations given the company's $1.4 billion market cap and recent growth trajectory. The forecast signals confidence in the commercial ramp of its ASSURE Wearable Cardioverter Defibrillator, which received an FDA-approved algorithm update in April. This follows a $149.3 million equity offering earlier this year, providing capital to support expansion. The guidance provides a concrete top-line target for the first time, giving traders a benchmark to measure execution against.
At the time of this announcement, KMTS was trading at $24.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $13.25 to $30.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.